Jason Ryan sold $3.3M of WGS
director at GeneDx Holdings Corp.. 47,000 shares at an average of $70.57, traded Nov 19, 2024, filed Nov 21, 2024.
Score components
- +15RoleDirector
- +25Trade size$3.3M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +7.4%, 3m +40.9%, 6m -6.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-027473, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 19, 2024 | GGift Class A Common Stockindirect: By Jason Ryan Trust u/a dtd 11/25/2018 | -141,356 | $0.00 | $0 | 47,000 | Nov 21, 2024 |
| Nov 19, 2024 | SOpen-market sale Class A Common Stockindirect: By Jason Ryan Trust u/a dtd 11/25/2018 | -5,952 | $70.86 | $422k | 41,048 | Nov 21, 2024 |
| Nov 19, 2024 | SOpen-market sale Class A Common Stockindirect: By Jason Ryan Trust u/a dtd 11/25/2018 | -24,784 | $71.35 | $1.8M | 16,264 | Nov 21, 2024 |
| Nov 19, 2024 | SOpen-market sale Class A Common Stockindirect: By Jason Ryan Trust u/a dtd 11/25/2018 | -774 | $72.26 | $56k | 15,490 | Nov 21, 2024 |
| Nov 20, 2024 | SOpen-market sale Class A Common Stockindirect: By Jason Ryan Trust u/a dtd 11/25/2018 | -9,361 | $68.36 | $640k | 6,129 | Nov 21, 2024 |
| Nov 20, 2024 | SOpen-market sale Class A Common Stockindirect: By Jason Ryan Trust u/a dtd 11/25/2018 | -1,857 | $69.84 | $130k | 4,272 | Nov 21, 2024 |
| Nov 20, 2024 | SOpen-market sale Class A Common Stockindirect: By Jason Ryan u/a dtd 11/25/2018 | -4,272 | $70.50 | $301k | 0 | Nov 21, 2024 |
Related signals
Other insiders at GeneDx Holdings Corp. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $364k 3,728 shares | -8% | |
| 43Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $1.0M 10,501 shares | -8% | |
| 25Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $108k 1,285 shares | -3% | |
| 32Weak | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $311k 3,692 shares | -3% | |
| 20Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $31k 372 shares | -1% | |
| 28Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $227k 3,729 shares | -9% | |
| 38Weak | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $638k 10,501 shares | -9% | |
| 23Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $68k 1,266 shares | -3% | |
| 30Weak | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $196k 3,639 shares | -4% | |
| 56Moderate | WGSbuy GeneDx Holdings Corp. | Casdin Capital, LLC director, owner | $11M 200,000 shares | +6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.